Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

Preoperative and Postoperative Nevanac 0.1% Compared to Acular LS for the Treatment of Ocular Inflammation Associated With Cataract Surgery

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00333255

Enrollment

267

Registered

2006-06-02

Start date

2005-09-30

Completion date

Unknown

Last updated

2009-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.

Interventions

DRUGNepafenac Ophthalmic Suspension, 0.1%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

10 Years to No maximum

Healthy volunteers

Inclusion criteria

* planned cataract extraction with posterior chamber intraocular lens implantation

Exclusion criteria

* Under 10

Design outcomes

Primary

Measure	Time frame
Percentage of patients who are a clinical success at Day 14 postoperative visit (where a clinical success is defined as aqueous cells < grade 1 and aqueous flare = grade 0 at the current visit and all subsequent visits).	—

Secondary

Measure	Time frame
Percentage of patients who are clinically cured, clinical successes, treatment failure, clinically significant inflammation	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026